0001728328 false A1 0001728328 2021-12-17 2021-12-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

December 17, 2021

(Date of Report - date of earliest event reported)

 

InMed Pharmaceuticals Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

British Columbia   001-39685   98-1428279

(State or Other Jurisdiction of

Incorporation or Organization)

  (Commission File Number)  

(I.R.S. Employer

Identification No.)

 

Suite 310 – 815 W. Hastings Street

Vancouver, B.C., Canada

 

V6C 1B4 

(Address of Principal Executive Offices)   (Zip Code)

 

(604) 669-7207

(Registrant's Telephone Number, Including Area Code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)  

Name of each exchange

on which registered

Common Shares, no par value   INM   The Nasdaq Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

Item 5.07: Submission of Matters to a Vote of Security Holders

 

On December 17, 2021, InMed Pharmaceuticals Inc., or the “Corporation”, held its Annual General Meeting of Shareholders.  At the meeting, shareholders voted in favor of all items of business, as indicated below:

 

Proposal No. 1—Election of Directors

 

The Corporation’s shareholders voted to elect the following persons to the board of directors of the Corporation, each to serve until the 2022 Annual General Meeting:

 

Nominee  Votes For   % Votes For  

Votes

Withheld

   %Votes Withheld  

Broker

Non-Votes

 
Eric A. Adams   2,960,270    93.98    189,717    6.02    2,821,286 
Adam Cutler   2,980,880    94.63    169,107    5.37    2,821,286 
William J. Garner   2,957,803    93.90    192,184    6.10    2,821,286 
Andrew Hull   2,980,096    94.61    169,891    5.39    2,821,286 
Catherine Sazdanoff   2,902,565    92.14    247,422    7.86    2,821,286 

 

Proposal No. 2—Appointment of Independent Registered Public Accounting Firm

 

The Corporation’s shareholders voted to approve the appointment of KPMG LLP as the independent registered public accounting firm of the Corporation until the next annual shareholders’ meeting or until a successor is named.

 

Votes For   % Votes For   Vote Against   % Votes Against   Abstain  

Broker

Non-Votes

 
 5,787,855    96.93    0    0.00    183,418    0 

 

Item 9.01 Exhibits.

 

(d) Exhibits.

 

Exhibit 99.1. News release, dated December 17, 2021
104

Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 

 

1

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: December 17, 2021

 

  INMED PHARMACEUTICALS INC.
     
  By: /s/ Bruce Colwill
  Name: Bruce Colwill
  Title: Chief Financial Officer

 

 

2 

 

 

Exhibit 99.1

 

 

NASDAQ: INM

 

Suite 310-815 W. Hastings St.

Vancouver, BC, Canada V6C 1B4

Tel: +1.604.669.7207

Email: info@inmedpharma.com

www.inmedpharma.com

 

InMed Announces Results of 2021 Annual General Meeting

 

Vancouver, BC – December 17, 2021 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today confirmed that, at its annual general meeting of shareholders held on December 17, 2021 (the “Meeting”), all of the matters put forward before shareholders for consideration and approval as set out in InMed’s notice of meeting and management information circular, dated October 28, 2021, were approved by the shareholders. In particular, shareholders approved the election of all director nominees to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. Results of the vote for the election of directors at the Meeting are set out as follows:

 

   Votes For   Withheld Votes 
Director  Number   Percentage   Number   Percentage 
Eric A. Adams   2,960,270    93.98%   189,717    6.02%
Adam Cutler   2,980,880    94.63%   169,107    5.37%
William J. Garner   2,957,803    93.90%   192,184    6.10%
Andrew Hull   2,980,096    94.61%   169,891    5.39%
Catherine Sazdanoff   2,902,565    92.14%   247,422    7.86%

 

InMed filed a report of voting results on SEDAR at www.sedar.com on December 17, 2021.

 

About InMed: InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary, BayMedica LLC, the Company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com and www.baymedica.com.

 

Investor Contact:

Colin Clancy

Senior Director, Investor Relations

T: +1 604 416 0999

E: cclancy@inmedpharma.com

 

Edison Group:

Joe Green/Laine Yonker

T: +1.646.653.7030/+1.646.653.7035

E: jgreen@edisongroup.com / lyonker@edisongroup.com

 

Cautionary Note Regarding Forward-Looking Information:

 

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about; being a global leader in the manufacturing and development of rare cannabinoids and delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs.

 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.